Summary of COVID-19 darunavir studies

42 patient darunavir late treatment study: 87% lower mortality (p=0.009).
Retrospective 110 critically ill COVID-19 patients in South Korea showing lower mortality with darunavir/cobicistat treatment.
Dec 2020, Yonsei Medical J., https://eymj.org/DOIx.php?id=10.3349/ymj.2020.61.9.826, https://c19p.org/kim25

2. Nicolini et al., Reply to: “Antiviral Activity and Safety of Darunavir/Cobicistat for Treatment of COVID-19”

328 patient darunavir late treatment study: 32% higher mortality (p=0.21).
Retrospective 328 hospitalized COVID-19 patients in Italy showing no mortality benefit with darunavir/ritonavir treatment.
Jul 2020, Open Forum Infectious Diseases, https://academic.oup.com/ofid/article/doi/10.1093/ofid/ofaa321/5877884, https://c19p.org/nicolini

3. Di Castelnuovo et al., Lopinavir/Ritonavir and Darunavir/Cobicistat in Hospitalized COVID-19 Patients: Findings From the Multicenter Italian CORIST Study

2,303 patient darunavir late treatment study: 89% higher mortality (p<0.0001).
Retrospective 3,451 hospitalized COVID-19 patients in Italy showing higher mortality with darunavir/cobicistat.
Jun 2021, Frontiers in Medicine, https://www.frontiersin.org/articles/10.3389/fmed.2021.639970/full, https://c19p.org/dicastelnuovo3

4. Chen et al., Antiviral Activity and Safety of Darunavir/Cobicistat for the Treatment of COVID-19

30 patient darunavir early treatment RCT: 22% worse viral clearance (p=0.64).
RCT 30 mild COVID-19 patients showing no benefit of darunavir/cobicistat compared to standard care for viral clearance.
Jun 2020, Open Forum Infectious Diseases, https://academic.oup.com/ofid/article/doi/10.1093/ofid/ofaa241/5860459, https://c19p.org/chen37

5. Milic et al., Darunavir/Cobicistat Is Associated with Negative Outcomes in HIV-Negative Patients with Severe COVID-19 Pneumonia

273 patient darunavir late treatment study: 150% higher mortality (p=0.0001) and 48% higher combined mortality/intubation (p=0.03).
Retrospective 273 hospitalized COVID-19 patients showing higher mortality with darunavir/cobicistat treatment.
Mar 2021, AIDS Research and Human Retroviruses, https://www.liebertpub.com/doi/10.1089/aid.2020.0305, https://c19p.org/milic

Submit Corrections or Updates

Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.

Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0